Stock INTS INTENSITY THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Intensity Therapeutics, Inc.

Equities

INTS

US45828J1034

Market Closed - Nasdaq
Other stock markets
 21:00:00 10/05/2024 BST 		5-day change 1st Jan Change
4 USD +6.38% Intraday chart for Intensity Therapeutics, Inc. +3.63% -53.33%
05-10 Intensity Therapeutics Collaborates With Swiss Group on Clinical Research for Breast Cancer Trial MT
05-10 Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Intensity Therapeutics Collaborates With Swiss Group on Clinical Research for Breast Cancer Trial
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate
Intensity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Intensity Therapeutics, Inc. Announces Resignation of Daniel Donovan from Audit Committee of the Board of Directors
Intensity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Intensity Therapeutics Names Joseph Talamo as Finance Chief
Sector Update: Health Care Stocks Rise Late Afternoon
Sector Update: Health Care
Top Midday Gainers
Intensity Therapeutics Says Breast Cancer Treatment Showed Tumor Necrosis in Phase 2 Trial; Shares Jump
Intensity Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Intensity Therapeutics, Inc. Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023
Intensity Therapeutics Gets Orphan Drug Label for Three Ingredients in INT230-6
Intensity Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Intensity Therapeutics Shares Surge in Nasdaq Debut After IPO Pricing
Intensity Therapeutics, Inc. has completed an IPO in the amount of $19.5 million.
Intensity Therapeutics, Inc. Announces Data from Its Ongoing Phase 1/2 Clinical Trial Demonstrating the Efficacy and Tolerability of Int230-6
Intensity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Intensity Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
Intensity Therapeutics, Inc. has completed an IPO in the amount of $8.1 million.
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INTS Stock
  4. News Intensity Therapeutics, Inc.
  5. Other languages